Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

American Family Physician March 15, 2005 Paul T. Giboney	Mildly Elevated Liver Transaminase Levels in the Asymptomatic Patient Mild elevations in liver chemistry tests can reveal serious underlying conditions or have transient and benign etiologies. If elevations persist after an appropriate period of observation, further testing may include ultrasonography and other serum studies.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
The Motley Fool December 16, 2011 Brian Orelli	Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool September 28, 2007 Brian Orelli	Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others.
Pharmaceutical Executive September 1, 2005 Mattingly & Saxberg	Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next.
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
The Motley Fool October 3, 2007 Brian Orelli	Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note.
Chemistry World November 2006 Derek Lowe	Opinion: In the Pipeline Is there a way to kill off bad drug candidates before companies invest valuable time and money and in them?
Chemistry World January 16, 2014	The art of alternatives Recent years have seen great advances in alternatives to animal tests. Yet we still need to understand how and why compounds are toxic before we can make the giant leap to replacement.
American Family Physician June 1, 2006	Nonalcoholic Fatty Liver Disease: What You Should Know A patient guide: What is nonalcoholic fatty liver disease (NAFLD)?... How can my doctor tell if I have NAFLD?... What can I expect?... etc.
American Family Physician June 1, 2006 Bayard, Holt & Boroughs	Nonalcoholic Fatty Liver Disease Nonalcoholic fatty liver disease is a common condition associated with metabolic syndrome. It is the most common cause of elevated liver enzymes in U.S. adults, and is diagnosed after ruling out other causes of steatosis, particularly infectious hepatitis and alcohol abuse.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
American Family Physician September 1, 2006 Heidelbaugh & Bruderly	Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation Part I of a two-part on how to diagnose and determine treatment for cirrhosis and chronic liver failure.
The Motley Fool June 20, 2008 Brian Orelli	Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
Nurse Practitioner July 2008 Lynn A. Kelso	Cirrhosis: Caring for Patients with End-stage Liver Failure Caring for patients with end-stage liver disease can be very challenging for NPs.
The Motley Fool September 7, 2007 Brian Orelli	Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug.
Chemistry World December 22, 2006 Victoria Gill	Metabolic Profiling Could Improve Animal Experiments Different types of rats respond to drugs in substantially different ways that can be tracked by metabolic analysis, according to scientists who say their finding has major implications for designing animal experiments.
Bio-IT World February 18, 2004	Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies
HHMI Bulletin Fall 2012 Sarah C. P. Williams	The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster.
HHMI Bulletin May 2010 Sarah C.P. Williams	Lab-Grown Liver New cell culture system solves problem of growing liver cells.
The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Chemistry World July 24, 2007 Richard Van Noorden	A Viable Alternative Tests on mice, rats, rabbits and guinea pigs to stop harmful chemicals reaching humans were once a necessary evil. But such checks now seem embarrassingly old-fashioned, according to a report on toxicity testing.
American Family Physician January 15, 2004 Roche & Kobos	Jaundice in the Adult Patient Jaundice in an adult patient can be caused by a wide variety of benign or life-threatening disorders. Organizing the differential diagnosis by prehepatic, intrahepatic, and posthepatic causes may help make the work-up more manageable.
American Family Physician September 1, 2006	Cirrhosis and Chronic Liver Failure: What You Should Know The basics about cirrhosis and chronic liver failure.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
Bio-IT World August 13, 2003 Malorye Branca	Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.
American Family Physician October 1, 2000 Kelly W. Jones, Pharm.D. & Supen R. Patel, M.D.	A Family Physician's Guide to Monitoring Methotrexate Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy...
Chemistry World March 26, 2014 Katia Moskvitch	Nanoparticle sensors detect drug damage in the liver Stanford University researchers have created nanoparticle-based sensors that can image metabolites in animal livers, which they say could help eliminate toxic drug candidates before they are given to humans.
Bio-IT World March 2006 Michael A. Greeley	The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain.
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
Chemistry World May 18, 2010 Sarah Houlton	EPA and pharma join forces The US Environmental Protection Agency is working with pharmaceutical companies to improve its ToxCast toxicity prediction tool.
American Family Physician March 15, 2004	Management of Hepatitis C: Evaluating Suitability for Drug Therapy Chronic hepatitis C virus infection is a common and serious disease. Although an estimated 2.7 million persons in the United States have this disease, most have not yet been diagnosed.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Chemistry World May 9, 2011 Sarah Houlton	Ecstasy substitute poses major health risks Scientists at Anglia Ruskin University haves shown that one of the most common 'legal high' designer drugs, benzylpiperazine, is not only dangerous when it's taken - repeated consumption poses major health risks.
Chemistry World August 7, 2012 Emma Eley	Improved drugs to treat malarial liver infection Antimalarial drugs with increased in vitro activity have been developed by scientists in Portugal and the US. These novel drugs, called primacins, are active against two stages of malarial infection.
Chemistry World July 15, 2008 Hepeng Jia	Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
Bio-IT World March 8, 2005 Patricia Reilly	Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending.
Nursing December 2008 Susan Simmons Holcomb	Caring for a patient with chronic hepatitis C Teach your patient about improved treatments that can help him deal with this potentially deadly infection.
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
American Family Physician November 1, 2001 Thomas R. Riley	Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise...